HLA-F in maternal-fetal immune crosstalks
HLA-F in maternal-fetal immune crosstalks
批准号:
10667879
负责人:
MARLENE BOUVIER
金额:
$23.99万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-09-22 至 2025-07-31
关键词:
AddressAminopeptidaseBindingBiochemicalBiological AssayBloodCell ShapeCellsCommunicationComplexDeciduaEndometriumEnsureFamilyFetusFirst Pregnancy TrimesterHLA-A geneHLA-B AntigensHLA-C AntigensImmuneImmune ToleranceImmunobiologyImmunoglobulinsImmunologicsIn VitroInvadedInvestigationKIR3DS1KnowledgeLengthLeukocytesMajor Histocompatibility ComplexMass Spectrum AnalysisMaternal-Fetal ExchangeMaternally-Acquired ImmunityMolecularNK cell receptor NKB1Natural Killer CellsPathologyPeptidesPhysiological ProcessesPlacentaPlayPopulationPregnancyPregnancy ComplicationsPropertyReceptor CellRiskRoleSchemeSpiral Artery of the EndometriumSpontaneous abortionSurfaceTissuesUterusVascular remodelingVillousWorkX-Ray Crystallographybiophysical techniquescell typeconformerdesignearly pregnancyfetalfetus cellhealthy pregnancyimmunoregulationimplantationinfant deathkiller inhibitory receptormigrationpregnancy disorderreceptortrophoblasttumor-immune system interactions
中文摘要
点击翻译按钮获取中文摘要
英文摘要
ABSTRACT
Pregnancy is a complex state that involves immune crosstalks between maternal cells in the decidua and
fetal cells. This communication plays an important role in protecting the fetus from rejection. Extravillous
trophoblasts (EVTs) are critical fetal cells that shape the immunological microenvironment at the maternal-fetal
(M-F) interface. EVTs express a unique set of major histocompatibility complex (MHC I) molecules on their
surfaces: the classical HLA-C and non-classical HLA-E, -F, and -G molecules. Quite exceptionally, EVTs do
not express HLA-A and HLA-B. HLA-C, -E, and -G molecules have been associated with mechanisms of
immune tolerance at the M-F interface, and whether HLA-F functions similarly is less well understood. HLA-F is
unique among MHC I molecules in several ways: 1. HLA-F exists in more than one molecular form, with and
without associated peptides and b2m; 2. HLA-F binds peptides that are unconventionally long, ranging from
8mers to more than 20mers; and 3. Inhibitory and activating receptors on natural killer (NK) cells can
distinguish between peptide-filled and peptide-deficient HLA-F molecules. It is therefore logical to propose that
a role for HLA-F in M-F immune crosstalks involves interactions between HLA-F expressed on EVTs and NK
receptors on decidual NK cells. This is reinforced by the knowledge that HLA-F expression on EVTs is most
abundant in early pregnancy, and that NK cells constitute the largest population of maternal immune cells in
the decidua during the first trimester of pregnancy. Thus, to develop an understanding of how HLA-F functions
as an immunoregulatory molecule, it is critical that we have a strong understanding of the peptide binding
properties of HLA-F and the mechanisms by which peptides modulate interactions with NK cell receptors. This
R21 application is an early-stage investigation that aims to fill unresolved gaps in our knowledge of HLA-F
immunobiology. In two aims, we propose to examine the unique landscape of HLA-F peptides in relation to
specialized aminopeptidases that normally generate MHC I immunopeptidomes inside cells, as well as address
key questions centered on why HLA-F presents peptides of extraordinarily long lengths, what biochemical and
structural properties of HLA-F support binding of long peptides, and what is the role of peptides in modulating
HLA-F interaction with NK cells. For this, we will use a combination of cell-based, biochemical, and structural
approaches. Upon completion of this project, we will have generated new knowledge on HLA-F that will help
understand how its expression on EVTs and engagement with receptors on decidual NK cells, can support a
critical regulatory role in immune crosstalks during the early stages of pregnancy. Given that pregnancy
complications are often associated with a loss of immune tolerance mechanisms, a characterization of HLA-F
as proposed here is important for stimulating new ideas in managing and decreasing the risks associated with
such complications.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Immune evasion by SARS-CoV-2: the role of HLA class I
-
批准号:10575292
-
项目类别:
-
资助金额:$23.99万
-
财政年份:2022
-
负责人:MARLENE BOUVIER
-
依托单位:
Understanding ERAP molecular mechanism of MHC I antigen processing
-
批准号:10180881
-
项目类别:
-
资助金额:$39.98万
-
财政年份:2017
-
负责人:MARLENE BOUVIER
-
依托单位:
Understanding ERAP molecular mechanism of MHC I antigen processing
-
批准号:9383415
-
项目类别:
-
资助金额:$39.98万
-
财政年份:2017
-
负责人:MARLENE BOUVIER
-
依托单位:
Small molecule inhibitors of adenovirus-induced downregulation of MHC I
-
批准号:9098588
-
项目类别:
-
资助金额:$7.58万
-
财政年份:2015
-
负责人:MARLENE BOUVIER
-
依托单位:
Subversion of MHC class I antigen presentation by viral immunomodulatory proteins
-
批准号:8996707
-
项目类别:
-
资助金额:$39.88万
-
财政年份:2014
-
负责人:MARLENE BOUVIER
-
依托单位:
Subversion of MHC class I antigen presentation by viral immunomodulatory proteins
-
批准号:9206412
-
项目类别:
-
资助金额:$39.88万
-
财政年份:2014
-
负责人:MARLENE BOUVIER
-
依托单位:
Subversion of MHC class I antigen presentation by viral immunomodulatory proteins
-
批准号:8723605
-
项目类别:
-
资助金额:$39.88万
-
财政年份:2014
-
负责人:MARLENE BOUVIER
-
依托单位:
Molecular mechanism of immune evasion by the E3-19K protein of Adenovirus
-
批准号:8532447
-
项目类别:
-
资助金额:$39.88万
-
财政年份:2012
-
负责人:MARLENE BOUVIER
-
依托单位:
Molecular mechanism of virus-mediated immune evasion
-
批准号:7284014
-
项目类别:
-
资助金额:$15.8万
-
财政年份:2006
-
负责人:MARLENE BOUVIER
-
依托单位:
Molecular mechanism of virus-mediated immune evasion
-
批准号:7559130
-
项目类别:
-
资助金额:$12.65万
-
财政年份:2006
-
负责人:MARLENE BOUVIER
-
依托单位:
CRYSTALLOGRAPHIC ANALYSIS OF HLA-A11 IN COMPLEX WITH SUBDOMINANT HIV-1 PEPTIDES
-
批准号:7181011
-
项目类别:
-
资助金额:$8.35万
-
财政年份:2005
-
负责人:MARLENE BOUVIER
-
依托单位:
CRYSTALLOGRAPHY: HLA-A11:HIV1 PEPTIDE COMPLEXES
-
批准号:6977173
-
项目类别:
-
资助金额:$8.35万
-
财政年份:2004
-
负责人:MARLENE BOUVIER
-
依托单位:
STRUCTURE OF HLA-A*1101 IN COMPLEX WITH HIV1 NEF
-
批准号:6977220
-
项目类别:
-
资助金额:$3.34万
-
财政年份:2004
-
负责人:MARLENE BOUVIER
-
依托单位:
Immune evasion by the Adenovirus E3-19K protein
-
批准号:6672040
-
项目类别:
-
资助金额:$7.35万
-
财政年份:2003
-
负责人:MARLENE BOUVIER
-
依托单位:
Immune evasion by the Adenovirus E3-19K protein
-
批准号:6764235
-
项目类别:
-
资助金额:$7.4万
-
财政年份:2003
-
负责人:MARLENE BOUVIER
-
依托单位:
HLA-ALL IN THE CELLULAR IMMUNE RESPONSE TO HIV-1
-
批准号:6374308
-
项目类别:
-
资助金额:$17.88万
-
财政年份:2000
-
负责人:MARLENE BOUVIER
-
依托单位:
IN VITRO FOLDING AND ASSEMBLY OF CLASS I MHC MOLECULES
-
批准号:6362405
-
项目类别:
-
资助金额:$21.02万
-
财政年份:2000
-
负责人:MARLENE BOUVIER
-
依托单位:
In vitro folding and assembly of class I MHC molecules
-
批准号:7264231
-
项目类别:
-
资助金额:$4.57万
-
财政年份:2000
-
负责人:MARLENE BOUVIER
-
依托单位:
In vitro folding and assembly of class I MHC molecules
-
批准号:8048987
-
项目类别:
-
资助金额:$29.42万
-
财政年份:2000
-
负责人:MARLENE BOUVIER
-
依托单位:
IN VITRO FOLDING AND ASSEMBLY OF CLASS I MHC MOLECULES
-
批准号:6510965
-
项目类别:
-
资助金额:$21.18万
-
财政年份:2000
-
负责人:MARLENE BOUVIER
-
依托单位:
海外基金